Ensuring Platform Transparency and Accountability
Summary
Open-source investigations and public interest research using platform data (e.g., Facebook, YouTube) have enabled the collection of evidence of human rights atrocities, identified the role of foreign adversaries in manipulating public opinion before elections, and uncovered the prevalence and reach of terrorist radicalization and recruitment tactics. Nascent data privacy legislation such as the EU General Data Protection Regulation and the California Consumer Privacy Act have placed increased pressure on platforms to restrict third party access to data. In an overly cautious interpretation of these laws, platforms are increasingly restricting third-party access to the data they collect. In doing so, platforms shield themselves from public scrutiny and accountability.
To support transparency and accountability of platforms, the next administration should work with Congress to ensure that any new data privacy legislation proposed at the federal level does not inadvertently block the ability of third parties to gain access to platform data for open-source investigations and public interest research. The White House Office of Science and Technology Policy should take the lead by convening a workshop among key actors to make progress on these goals. Out of the workshop, a federal working group should be formed to develop principles and operational guides to support ethical third-party access to platform data, including the formation of technical standards to ensure data privacy and security.
AI is transforming how children learn and live, and policymakers, industry, and educators owe it to the next generation to set in place a responsible policy that embraces this new technology while at the same time ensuring all children’s well-being, privacy, and safety is respected.
A peer support option should be integrated into the 988 Suicide and Crisis Lifeline so that 988 service users can choose to connect with specialists based on a shared lived experience.
Given the rapid pace of AI advancement, a proactive effort triumphs over a reactive one. To protect consumers, workers, and the economy more broadly, it is imperative that the FTC and DOJ adapt their enforcement strategies to meet the complexities of the AI era.
To encourage greater adoption of generic drugs in clinical practice the FDA should implement a dedicated regulatory pathway for non-manufacturers to seek approval of new indications for repurposed generic drugs.